IP Library › Granted Patent US 12,344,601
Granted Patent B2
US 12,344,601 · App. 18/216,669 · Granted Jul 1, 2025

(cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Inventors: Doris Riether (Biberach an der Riss, DE); Florian Paul Christian Binder (Maselheim, DE); Henri Doods (Warthausen, DE); Stephan George Mueller (Warthausen, DE); Janet Rachel Nicholson (Oberhoefen, DE); Achim Sauer (Ravensburg-Torkenweiler, DE)
Assignee: Centrexion Therapeutics Corporation
C07D417/12A61K31/422C07D261/04C07D261/14C07D413/02C07D413/12C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,601
App. No.
18/216,669
Granted
Jul 1, 2025
Kind
B2
Abstract

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

Claims (21)

1. A method of treating pain selected from the group consisting of acute pain, visceral pain, and neuropathic pain, comprising administering to a human being an effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of

and a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier, to treat the pain.

2. The method of claim 1 , wherein the compound is

3. The method of claim 1 , wherein the pain is acute pain.

4. The method of claim 2 , wherein the pain is acute pain.

5. The method of claim 3 , wherein the acute pain is trigeminal neuralgia.

6. The method of claim 4 , wherein the acute pain is trigeminal neuralgia.

7. The method of claim 1 , wherein the pain is visceral pain.

8. The method of claim 2 , wherein the pain is visceral pain.

9. The method of claim 1 , wherein the pain is neuropathic pain.

10. The method of claim 2 , wherein the pain is neuropathic pain.

11. The method of claim 9 , wherein the neuropathic pain is post-herpetic neuralgia.

12. The method of claim 10 , wherein the neuropathic pain is post-herpetic neuralgia.

13. The method of claim 9 , wherein the neuropathic pain is due to chemotherapy caused nerve injury.

14. The method of claim 10 , wherein the neuropathic pain is due to chemotherapy caused nerve injury.

15. The method of claim 9 , wherein the neuropathic pain is due to central nervous system injury.

16. The method of claim 10 , wherein the neuropathic pain is due to central nervous system injury.

17. The method of claim 9 , wherein the neuropathic pain is due to diabetic neuropathy.

18. The method of claim 10 , wherein the neuropathic pain is due to diabetic neuropathy.

19. The method of claim 9 , wherein the neuropathic pain is due to diabetic peripheral neuropathy.

20. The method of claim 10 , wherein the neuropathic pain is due to diabetic peripheral neuropathy.

Assignments (3)
SECURITY INTEREST Recorded Nov 21, 2025
From: CENTREXION THERAPEUTICS CORPORATION
To: ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 073683/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2023
From: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 064370/0783 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2023
From: RIETHER, DORIS; BINDER, FLORIAN PAUL CHRISTIAN; DOODS, HENRI; MUELLER, STEPHAN GEORG; NICHOLSON, JANET RACHEL; SAUER, ACHIM
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 064371/0111 →
Priority Claims (1)
EP 13168165 · May 17, 2013 · regional
Continuity (6)
Continuation 17398155 · Aug 10, 2021
Continuation 16749412 · Jan 22, 2020
Continuation 16143523 · Sep 27, 2018
Continuation 15491035 · Apr 19, 2017
Continuation 14891051
Related Publication 20240092769A1 · Mar 21, 2024
References Cited (348)
US 3116284A · Testa · 1963 [cited by applicant]
US 3117128A · Mooradian · 1964 [cited by applicant]
US 3577462A · Bruce et al. · 1971 [cited by applicant]
US 3966809A · Baker et al. · 1976 [cited by applicant]
US 4257954A · Schmidt et al. · 1981 [cited by applicant]
US 4535087A · Spatz · 1985 [cited by applicant]
US 4672065A · Spatz · 1987 [cited by applicant]
US 4734125A · Gehring et al. · 1988 [cited by applicant]
US 4859707A · Loftsson et al. · 1989 [cited by applicant]
US 5256658A · Hsi et al. · 1993 [cited by applicant]
US 5428037A · Pascal et al. · 1995 [cited by applicant]
US 5475130A · Sato et al. · 1995 [cited by applicant]
US 5491170A · Lee et al. · 1996 [cited by applicant]
US 5571921A · Bender et al. · 1996 [cited by applicant]
US 5583147A · Ko et al. · 1996 [cited by applicant]
US 5656634A · Chang et al. · 1997 [cited by applicant]
US 5834490A · Verde-Casanova et al. · 1998 [cited by applicant]
US 5847153A · Warpehoski et al. · 1998 [cited by applicant]
US 5958940A · Rane et al. · 1999 [cited by applicant]
US 5968929A · Blythin et al. · 1999 [cited by applicant]
US 6057371A · Glennon · 2000 [cited by applicant]
US 6176442B1 · Eicher et al. · 2001 [cited by applicant]
US 6221866B1 · Brendel et al. · 2001 [cited by applicant]
US 6355653B1 · Trottmann et al. · 2002 [cited by applicant]
US 6359009B1 · Diehl et al. · 2002 [cited by applicant]
US 6410792B1 · Connell et al. · 2002 [cited by applicant]
US 6414011B1 · Hogenkamp et al. · 2002 [cited by applicant]
US 6437177B1 · Warpehoski et al. · 2002 [cited by applicant]
US 6453795B1 · Eicher et al. · 2002 [cited by applicant]
US 6528529B1 · Brann et al. · 2003 [cited by applicant]
US 6573278B2 · Mittendorf et al. · 2003 [cited by applicant]
US 6610711B2 · Armer et al. · 2003 [cited by applicant]
US 6737418B2 · Hogenkamp et al. · 2004 [cited by applicant]
US 6756404B2 · Livinghouse · 2004 [cited by applicant]
US 6930115B2 · Fujii et al. · 2005 [cited by applicant]
US 7476756B2 · Almario-Garcia et al. · 2009 [cited by applicant]
US 7585881B2 · Edwards et al. · 2009 [cited by applicant]
US 7595397B2 · Zindell et al. · 2009 [cited by applicant]
US 7776897B2 · Murakami et al. · 2010 [cited by applicant]
US 7928123B2 · Berry et al. · 2011 [cited by applicant]
US 7935715B2 · Berry et al. · 2011 [cited by applicant]
US 8048899B2 · Bartolozzi et al. · 2011 [cited by applicant]
US 8173638B2 · Berry et al. · 2012 [cited by applicant]
US 8178568B2 · Regan et al. · 2012 [cited by applicant]
US 8299103B2 · Bartolozzi et al. · 2012 [cited by applicant]
US 8299111B2 · Berry et al. · 2012 [cited by applicant]
US 8329735B2 · Ermann et al. · 2012 [cited by applicant]
US 8349871B2 · Bartolozzi et al. · 2013 [cited by applicant]
US 8362039B2 · Bartolozzi et al. · 2013 [cited by applicant]
US 8372874B2 · Bartolozzi et al. · 2013 [cited by applicant]
US 8383615B2 · Hickey et al. · 2013 [cited by applicant]
US 8546563B2 · Berry et al. · 2013 [cited by applicant]
US 8629157B2 · Berry et al. · 2014 [cited by applicant]
US 8735430B2 · Bartolozzi et al. · 2014 [cited by applicant]
US 8778950B2 · Jones et al. · 2014 [cited by applicant]
US 8829034B2 · Berry et al. · 2014 [cited by applicant]
US 8846936B2 · Hickey et al. · 2014 [cited by applicant]
US 8865744B1 · Riether et al. · 2014 [cited by applicant]
US 8889670B2 · Bartolozzi et al. · 2014 [cited by applicant]
US 8957063B2 · Cirillo et al. · 2015 [cited by applicant]
US 9650370B2 · Riether et al. · 2017 [cited by applicant]
US 10112934B2 · Riether et al. · 2018 [cited by applicant]
US 10570125B2 · Riether et al. · 2020 [cited by applicant]
US 11084810B2 · Riether et al. · 2021 [cited by applicant]
US 11725004B2 · Riether et al. · 2023 [cited by applicant]
US 20020099035A1 · Sandanayaka et al. · 2002 [cited by applicant]
US 20040067999A1 · Block et al. · 2004 [cited by applicant]
US 20040152747A1 · Chen et al. · 2004 [cited by applicant]
US 20040242666A1 · Chen · 2004 [cited by applicant]
US 20040242913A1 · Ducray et al. · 2004 [cited by applicant]
US 20050059663A1 · Martin et al. · 2005 [cited by applicant]
US 20050182108A1 · Carson et al. · 2005 [cited by applicant]
US 20050222219A1 · Chen · 2005 [cited by applicant]
US 20060009491A1 · Yao et al. · 2006 [cited by applicant]
US 20060061726A1 · Okuyama · 2006 [cited by applicant]
US 20060079557A1 · Dolle et al. · 2006 [cited by applicant]
US 20060173022A1 · Schaper · 2006 [cited by applicant]
US 20070021403A1 · Abouabdellah et al. · 2007 [cited by applicant]
US 20070021430A1 · Chen et al. · 2007 [cited by applicant]
US 20070093501A1 · Kubo et al. · 2007 [cited by applicant]
US 20070179126A1 · Casellas et al. · 2007 [cited by applicant]
US 20070191340A1 · Zindell et al. · 2007 [cited by applicant]
US 20070213311A1 · Li et al. · 2007 [cited by applicant]
US 20070270426A1 · Chen · 2007 [cited by applicant]
US 20080039464A1 · Berry et al. · 2008 [cited by applicant]
US 20080064690A1 · Atkinson et al. · 2008 [cited by applicant]
US 20080081342A1 · Fung · 2008 [cited by applicant]
US 20080081822A1 · Berry et al. · 2008 [cited by applicant]
US 20080227781A1 · Bradney et al. · 2008 [cited by applicant]
US 20090163545A1 · Goldfarb · 2009 [cited by applicant]
US 20090275611A1 · Riether et al. · 2009 [cited by applicant]
US 20100009964A1 · Berry et al. · 2010 [cited by applicant]
US 20100029644A1 · Riether et al. · 2010 [cited by applicant]
US 20100076029A1 · Bartolozzi et al. · 2010 [cited by applicant]
US 20100081644A1 · Bartolozzi et al. · 2010 [cited by applicant]
US 20100261708A1 · Cirillo et al. · 2010 [cited by applicant]
US 20100331304A1 · Berry et al. · 2010 [cited by applicant]
US 20110071127A1 · Berry et al. · 2011 [cited by applicant]
US 20110071196A1 · Bartolozzi et al. · 2011 [cited by applicant]
US 20110124696A1 · Regan et al. · 2011 [cited by applicant]
US 20110130431A1 · Berry et al. · 2011 [cited by applicant]
US 20110136869A1 · Bartolozzi et al. · 2011 [cited by applicant]
US 20110190256A1 · Cirillo et al. · 2011 [cited by applicant]
US 20110312932A1 · Bartolozzi et al. · 2011 [cited by applicant]
US 20110312944A1 · Bartolozzi et al. · 2011 [cited by applicant]
US 20120010184A1 · Bartolozzi et al. · 2012 [cited by applicant]
US 20120015988A1 · Hickey et al. · 2012 [cited by applicant]
US 20120071529A1 · Ermann et al. · 2012 [cited by applicant]
US 20120142666A1 · Hickey et al. · 2012 [cited by applicant]
US 20120142677A1 · Berry et al. · 2012 [cited by applicant]
US 20120316173A1 · Bartolozzi et al. · 2012 [cited by applicant]
US 20190161481A1 · Riether et al. · 2019 [cited by applicant]
CH 312963A · 1956 [cited by applicant]
DE 1080563B · 1960 [cited by applicant]
DE 3636278A1 · 1988 [cited by applicant]
EP 0628555A1 · 1994 [cited by applicant]
EP 0929519A1 · 1999 [cited by applicant]
EP 0970046A1 · 2000 [cited by applicant]
EP 1790641A1 · 2007 [cited by applicant]
FR 2866885A1 · 2005 [cited by applicant]
FR 2872813A1 · 2006 [cited by applicant]
GB 853799A · 1960 [cited by applicant]
GB 884258A · 1961 [cited by applicant]
GB 1237126A · 1971 [cited by applicant]
JP S6127905A · 1986 [cited by applicant]
JP S6127955A · 1986 [cited by applicant]
JP S61126071A · 1986 [cited by applicant]
JP 2003155285A · 2003 [cited by applicant]
JP 2006504796A · 2006 [cited by applicant]
JP 2006143667A · 2006 [cited by applicant]
JP 2006525990A · 2006 [cited by applicant]
JP 2007502828A · 2007 [cited by applicant]
JP 2007530525A · 2007 [cited by applicant]
JP 2007530661A · 2007 [cited by applicant]
WO WO9405628A1 · 1994 [cited by applicant]
WO WO9407607A1 · 1994 [cited by applicant]
WO WO9626925A1 · 1996 [cited by applicant]
WO WO9712683A1 · 1997 [cited by applicant]
WO WO9712687A1 · 1997 [cited by applicant]
WO WO9720590A1 · 1997 [cited by applicant]
WO WO9746556A1 · 1997 [cited by applicant]
WO WO9808295A1 · 1998 [cited by applicant]
WO WO9811097A1 · 1998 [cited by applicant]
WO WO9813340A1 · 1998 [cited by applicant]
WO WO9838163A1 · 1998 [cited by applicant]
WO WO9965889A1 · 1999 [cited by applicant]
WO WO0008015A2 · 2000 [cited by applicant]
WO WO0100573A1 · 2001 [cited by applicant]
WO WO0129007A1 · 2001 [cited by applicant]
WO WO0164651A1 · 2001 [cited by applicant]
WO WO02051806A1 · 2002 [cited by applicant]
WO WO02062750A1 · 2002 [cited by applicant]
WO WO02088089A1 · 2002 [cited by applicant]
WO WO03037274A2 · 2003 [cited by applicant]
WO WO03055482A1 · 2003 [cited by applicant]
WO WO03074493A1 · 2003 [cited by applicant]
WO WO2004000807A1 · 2003 [cited by applicant]
WO WO2004014370A2 · 2004 [cited by applicant]
WO WO2004014825A1 · 2004 [cited by applicant]
WO WO2004014902A2 · 2004 [cited by applicant]
WO WO2004018433A1 · 2004 [cited by applicant]
WO WO2004026301A1 · 2004 [cited by applicant]
WO WO2004029027A1 · 2004 [cited by applicant]
WO WO2004042351A2 · 2004 [cited by applicant]
WO WO2004050643A2 · 2004 [cited by applicant]
WO WO2004060882A1 · 2004 [cited by applicant]
WO WO2004099200A1 · 2004 [cited by applicant]
WO WO2004099205A1 · 2004 [cited by applicant]
WO WO2005027837A2 · 2005 [cited by applicant]
WO WO2005040355A2 · 2005 [cited by applicant]
WO WO2005044797A1 · 2005 [cited by applicant]
WO WO2005068448A1 · 2005 [cited by applicant]
WO WO2005077345A1 · 2005 [cited by applicant]
WO WO2005077368A2 · 2005 [cited by applicant]
WO WO2005077373A2 · 2005 [cited by applicant]
WO WO2005085227A1 · 2005 [cited by applicant]
WO WO2006000031A1 · 2006 [cited by applicant]
WO WO2006012227A2 · 2006 [cited by applicant]
WO WO2006030805A1 · 2006 [cited by applicant]
WO WO2006060461A1 · 2006 [cited by applicant]
WO WO2006074445A2 · 2006 [cited by applicant]
WO WO2006080040A1 · 2006 [cited by applicant]
WO WO2006095159A1 · 2006 [cited by applicant]
WO WO2006100502A1 · 2006 [cited by applicant]
WO WO2006117461A2 · 2006 [cited by applicant]
WO WO2007020502A2 · 2007 [cited by applicant]
WO WO2007054770A2 · 2007 [cited by applicant]
WO WO2007070760A2 · 2007 [cited by applicant]
WO WO2007080382A1 · 2007 [cited by applicant]
WO WO2007102059A1 · 2007 [cited by applicant]
WO WO2007118041A1 · 2007 [cited by applicant]
WO WO2007140385A2 · 2007 [cited by applicant]
WO WO2008014199A2 · 2008 [cited by applicant]
WO WO2008023159A1 · 2008 [cited by applicant]
WO WO2008039645A1 · 2008 [cited by applicant]
WO WO2008048914A1 · 2008 [cited by applicant]
WO WO2008064054A2 · 2008 [cited by applicant]
WO WO2008098025A1 · 2008 [cited by applicant]
WO WO2008104994A2 · 2008 [cited by applicant]
WO WO2009055357A1 · 2009 [cited by applicant]
WO WO2009061652A1 · 2009 [cited by applicant]
WO WO2009077533A1 · 2009 [cited by applicant]
WO WO2009086303A2 · 2009 [cited by applicant]
WO WO2009105509A1 · 2009 [cited by applicant]
WO WO2009140089A2 · 2009 [cited by applicant]
WO WO2010005782A1 · 2010 [cited by applicant]
WO WO2010036630A2 · 2010 [cited by applicant]
WO WO2010036631A2 · 2010 [cited by applicant]
WO WO2010077836A2 · 2010 [cited by applicant]
WO WO2010096371A2 · 2010 [cited by applicant]
WO WO2010147791A1 · 2010 [cited by applicant]
WO WO2010147792A2 · 2010 [cited by applicant]
WO WO2011009883A1 · 2011 [cited by applicant]
WO WO2011035159A1 · 2011 [cited by applicant]
WO WO2011037795A1 · 2011 [cited by applicant]
WO WO2011088015A1 · 2011 [cited by applicant]
WO WO2011109324A1 · 2011 [cited by applicant]
WO WO2012012307A1 · 2012 [cited by applicant]
Parikh “Preventive analgesia: Effect of small dose of ketamine on morphine requirement after renal surgery” Journal of Anaesthesiology Clinical Pharmacology, Oct.-Dec. 2011, vol. 27, Issue 4, p. 485-488. [cited by examiner]
Anisimov, A. V. et al., “Synthesis of Sulfonyl and Sulfenyl Derivatives of Pyridine and 1,2,4-Triazole”, Russian Journal of Organic Chemistry, 2006, 42(6):918-921. [cited by applicant]
Aranapakam, V. et al., “Synthesis and Structure—Activity Relationship of a-Sulfonylhydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the treatment of Osteoarthritis”, J. Med. Chem., 2003, … [cited by applicant]
Aranapakam, V. et al., “Synthesis and Structure—Activity relationship of n-Substituted 4-Arylsulfonylpiperidine-4-hydroxamic Acids as Novel, Orally Active matrix Metalloproteinase Inhibitors for the treatment of Osteoar… [cited by applicant]
Aranapakam, V. et al., “Synthesis and Structure - Activity relationships of 4- alkynyloxy Phenyl Sulfanyl, Sulfinyl, and Sulfonyl Alkyl Hydroxamates as Tumor Necrosis Factor—a Converting Enzyme and Matrix Metalloprotein… [cited by applicant]
Arevalo-Martin, A. et al., “Therapeutic Action of Cannabinoids in a Murine model of Multiple Sclerosis”, J. of Neuroscience, 2003, 23(7):2511. [cited by applicant]
Atwell, G. J. et al., “Relationships between Structure and Kinetics of Cyclization of 2-Aminoaryl Amides: Potential Prodrugs of Cyclization-Activated Aromatic Mustards,” J. Med. Chem, 1994, 37:371-380. [cited by applicant]
Audouze, K. et al., “New series of morpholine and 1,4-oxazepane derivatives as dopamine D4 receptor ligands: Synthesis and 3D-QSAR model.” J. Med. Chem, 2004, 47(12):3089-3104. [cited by applicant]
Bair, K. W et al., “(1-pyrenylmethyl) amino alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies”. J. Med. Chem., 1990, 33:2385-2393. [cited by applicant]
Baker, D. et al., “Cannabinoids control spasticity and tremor in a multiple sclerosis model”, Nature, 2000, 404:84. [cited by applicant]
Baltzly, R. et al., “The preparation of N-mono-substituted and unsymmetrically disubstituted piperazines”. J. Am. Chem. Soc., 1944, 66:263-265. [cited by applicant]
Baltzly, R. et al., “Unsymmetrically substituted piperazines. V. Piperazine ureas”, The Journal of the American Chemical Society, 1954, 76:1165-1166. [cited by applicant]
Balzarini, J. et al., “Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics”. J. Med. Chem., 2003, 46(13):2755-2764. [cited by applicant]
Beilstein Database—Beilstein Registry No. 1084348. CAS Registry No. 6125-38-8, dated Sep. 1, 2010. [cited by applicant]
Beilstein Database—Beilstein Registry No. 1179643. CAS Registry No. 54890-73-2, dated Sep. 1, 2010. [cited by applicant]
Beilstein Database—Beilstein Registry No. 5396840. CAS Registry No. 54890-82-3, dated Sep. 1, 2010. [cited by applicant]
Beilstein Database—Beilstein Registry No. 5398283. CAS Registry No. 68558-02-01, dated Sep. 1, 2010. [cited by applicant]
Beilstein Database—Beilstein Registry No. 857451. CAS Registry No. 37901-58-9, dated Sep. 1, 2010. [cited by applicant]
Binisti, C. et al., “Structure-Activity relationships in platelet-activating factor (PAF). 11-From PAF-antagonism to phospholipase A2 inhibition: syntheses and structure-activity relationships in 1-arylsulfamido-2-alkyl… [cited by applicant]
Brown. P. J. et al., “A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity”, J. Med. Chem., 1999, 42(19):3785-3788. [cited by applicant]
Bruche, L. et al., “1,3-Dipolar cycloadditions of 3,5-dichloro-2,4,6-trimethylbenzonitrile oxide to (phenylsulfonyl)allenes”, J. Org. Chem., 1985, 50(17):3206-3208. [cited by applicant]
Buckley, N. E. et al., “Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor”, Eur. J. Pharmacology, 2000, 396(2-3):141-149. [cited by applicant]
CAplus Database—Accession No. 1967:454417, Kunieda et al., Chem. Pharm. Bull. vol. 15, No. 3, pp. 350-351 (1967). (Abstract Only). [cited by applicant]
CAplus Database—Accession No. 1976:58806; Retrieved on Jan. 2, 2009; Babayan, A.T. et al. “Intramolecular rearrangement of ammonium ylide formed by the splitting of substituted dihydroisoindolinium salts,” Doklady Akade… [cited by applicant]
CAplus Database—Accession No. 1990:497413; Zara-Kaczian, Acta Chimica Hungarica (1989), vol. 126, pp. 441-454. (Abstract Only). [cited by applicant]
CAplus Database—Accession No. 2000:500169; Retrieved on Jan. 2, 2009; Tommasi, R. A. et al. “AutoChem: automated solution-phase parallel synthesis and purification via HPLC,” J. Combinatorial Chem. (2000) vol. 2, pp. 44… [cited by applicant]
CAplus Database—Accession No. 2000:98008; Retrieved on Jan. 2, 2009; Organ, M. G. and Dixon, C. E. “The preparation of amino-substituted biaryl libraries: the application of solid-supported reagents to streamline soluti… [cited by applicant]
Carenzi, A, et al., “New Isoxazole Derivatives Provided with Antihypertensive Activity”, Arzneimittelforschung, 1989, 39(6):642-646. [cited by applicant]
Cartwright, D., et al., “Abnormal Nucleophillic substitution in 3-trichloromethylpyridine, its N- oxide and 3,5-Bis (trichloromethyl)pyridine”. Tetrahedron, Elsevier Science Publishers, Amsterdam, 1995, 51(47):12791-127… [cited by applicant]
Catalano, A. et al., “Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents”, European Journal of Medicinal Chemistry, 2008, 43(11):2535-2540. [cited by applicant]
Chang. M. Y et al., “Reaction of different α-sulfonyl acetamides with methyl acrylate”, Tetrahedron, 2008, 58(25):5075-5080. [cited by applicant]
Chem Abstract—Accession No. 126:89390, Abstract of JP8311026, Kumaiai Chemical Industry Co., Nov. 26, 1996. [cited by applicant]
ChemAbstract: CAS Registry No. 246020-62-2 (STN Entry Date Nov. 3, 1999). [cited by applicant]
Chemabstracts, Ukraine. Order Nos. T6110295, T5962700, T5962703 abstract and “Enamine Screening Library”, Jan. 1, 2009, Enamine, 23 Alexandra Matrosova SI., 01103 Kiev, Ukraine. [cited by applicant]
ChemAbstracts: CAS Registry Nos. 693218-49-4 (STN Entry Date Jun. 15, 2004) and 402562-90-7 (STN Entry Date Mar. 22, 2002). [cited by applicant]
Chen, D. et al., “Preparation, Properties, and Synthetic Potentials of Novel Boronates in a Fluorous Version (Fluorous Boronates)”, Organic Letters, 2002, 4(6):1003-1005. [cited by applicant]
Clark, N. G. et al., “The Fungicidal Activity of Substituted Acetanilides and Related Compounds”, Biochemical Journal, 1953, 55(5):839-851. [cited by applicant]
Cockcroft, X.-L. et al., “Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase”, Bioorg Med Chem Lett., 2006, 16(4):1040-1044. [cited by applicant]
Conway “Solid Dosage Forms” in Pharmaceutical Manufacturing Handbook: Production and Processes, edited by Shayne Cox Gad 2008 John Wiley & Sons, Inc., pp. 235-265. [cited by applicant]
Database PubChem Substance, 2005, Retrieved online from to: http://www.ncbi.nlm.nih.gov/pcsubstance. [cited by applicant]
Day, Jr., R. A. and Blanchard, W. A., “Polarography of phenyl 2-thienyl and 2,2′-dithienyl ketones,” J. Am. Chem. Soc., 1954, 76(4):1166-1167. [cited by applicant]
El-Hawash, S. A. M., et al., “Synthesis and invitro-Anticancer and Antimicrobial Evaluation of Some Novel Quinoxalines Derived from 3-Phenylquinoxaline-2(1 H)-thione”, Arch. Pharm. Chem. Life Sci., 2006, 339(8):437-447. [cited by applicant]
Ermann, M. et al. “Discovery of a novel class of CB2 receptor agonists”. Presented at the 14th SCI-RSC Medicinal Chemistry Symposium, Churchill College, Cambridge, UK, Sep. 23-26, 2007. (Abstract Only). [cited by applicant]
Ermann, M. et al. “Discovery of a novel class of CB2 receptor agonists”. Presented at the Cambridge Healthcare institute's 15th International Molecular Medicine Tri-Conference, Moscone Convention Center, San Francisco, … [cited by applicant]
Ermann, M. et al., “Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity”, Bioorg Med Chem Lett., 2008, 18(5):1725-1729. [cited by applicant]
Evans, W. J. et al., “A Rearrangement of Carbamyl-sulphones and -sulphides”, Journal of the Chemical Society, 1936, p. 329-331. [cited by applicant]
Faucher, A. M. et al., “Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase”, J. Med. Chem., 2004, 47(1):18-21. [cited by applicant]
Field, L. et al. “Grignard Reagents of Sulfones. IV. Reactions with Nitriles, Esters and an Isocyanate,” J. Am. Chem. Soc., 1956, 78(17):4389-4394. [cited by applicant]
Field, L., et al., “Methyl p-Tolyl Sulfone”, Organic Syntheses, Coll. vol. 4, p. 674, 1963; vol. 38, p. 62, (1958). [cited by applicant]
Fringuelli, F. et al., “Solvent-Free Al(OTf)3-Catalyzed Aminolysis of 1,2-Epoxides by 2-Picolylamine: A Key Step in the Synthesis of Ionic Liquids”. J. Org. Chem., 2004, 69(22):7745-7747. [cited by applicant]
Gao, M., et al. “Synthesis of new carbon-11 labeled benzoxazole derivatives for PET imaging of 5-HT3 receptor,” Eur. J. Med. Chem., 2008, 43(7):1570-1574. [cited by applicant]
Garst, M., et al., “Hydroformylation of bisolefinic amine derivatives catalyzed by cobalt and rhodium,” J. Org. Chem., 1981, 46(22):4433-4438. [cited by applicant]
Gavalda, S. et al. “N-Sulfonyl hydroxamate derivatives as inhibitors of class II fructose-1,6-diphosphate aldolase,” Bioorg Med Chem Lett., 2005, 15(24):5375-5377. [cited by applicant]
Goldschmidt. St. et al., “Biphenyl derivatives II. Basic 4-Biphenyl Compounds”, Recueil des Travaux Chimiques des Pays-Bas, 1950, 69(9):1109-1117. [cited by applicant]
Grothe, W. “Effect of Potassium Sulfhydrate, Potassium Cyanide, and Potassium Rhodanide on Chloroacetvlanilides,” Archiv der Pharmazie (Weinheim), vol. 238, 1900, 600-614. [cited by applicant]
Guindon, J. and Hohmann, A. G., “Cannabinoid CB2 Receptors: A Therapeutic Target for the Treatment of Inflammatory and Neuropathic Pain”, British Journal of Pharmacology, 2008, 153(2):319-334. [cited by applicant]
Hadjipavlou-Litina, D. et al., “Thiazolyl-N-Substituted Amides: A group of effective anti-inflammatory agents with potential for local anesthetic properties. Synthesis, Biological Evaluation, and a QSAR Approach”, Drua … [cited by applicant]
Hanus, L. et al., “HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor”, PNAS, 1999, 96(25):14228-14233. [cited by applicant]
Hauske, J. et al., “Design and Synthesis of Novel FKBP Inhibitors.” Journal of Medicinal Chemistry, 1992, 35(23):4284-4296. [cited by applicant]
Herndon, J. L. et al., “Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding”. J. Med. Chem, 1992, 35(26):4903-4910. [cited by applicant]
Ho, B. et al., “Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores,” Eur. J. Med. Chem., 2001, 36(3):265-286. [cited by applicant]
Huang, X. et al., “A Novel Synthesis of Sulfones via the 0.0-Diethylphosphorotellurite Ion-Assisted Coupling of Arenesulfonyl Chlorides with Active Halides”, Synthetic Communications, 1990, 20(15):2291-2295. [cited by applicant]
Ibrahim, M. M. et al., “Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS”, PNAS, 2003, 100(18):10529-10533. [cited by applicant]
Iddon, B. et al., “Condensed thiophen ring systems. Part XVII. A new synthesis of 10H-indeno[1,2-b][1]benzothiophen”, Journal of the Chemical Society. Perkin Transactions 1, Jan. 1, 1974, 21:2505-2508. [cited by applicant]
Iddon, B. et al., “Polyhalogenoaromatic compounds. Part 42. 13C N.m.r. spectra of polyhalogeno-pyridines and -pyrimidines”, Journal of the Chemical Society, Perkin Transactions 1, 1980, pp. 1370-1380. [cited by applicant]
Igarashi, J. et al., “Improved synthesis of quinine alkaloids with the Teoc protective group”, Tetrahedron Letters, 2005, 46(37):6381-6384. [cited by applicant]
International Search Report and Written Opinion for PCT/EP2014/060033 mailed Jul. 3, 2014. [cited by applicant]
Ishii, K. et al., “Smiles Rearrangement of 2-(1-Methyl-1 H-tetrazol-5-ylthio) acetamides and their Sulfonyl Derivatives”, Chem. Pharm. Bull., 1991, 39(12):3331-3334. [cited by applicant]
Iwakubo, M. et al., “Design and synthesis of Rho kinase inhibitors (II)”, Bioorg. Med. Chem., 2006, 15(1):350-364. [cited by applicant]
Jaggar, S. I. et al., “The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain”, Pain, 1998, 76(1-2):189-199. (Ab… [cited by applicant]
Johansen et al., AMPA Receptor Agonists: Resolution, Configurational Assignment, and Pharmacology of (+)-(S)- and (−)-(R)-2-Amino-3-(3-Hydroxy-5-(2-Pyridyl) Isoxazol-4-y1)Propionic Acid (1-Py-AMPA); Chirality, New York,… [cited by applicant]
Kano, S. et al., “Formation of Some Heterocycles through Ring Transformation of 1-Arylazetidin-2-ones”, Heterocycles, Dec. 30, 1977, 8(1):411-416. [cited by applicant]
Katoh, A., et al., “Synthesis of 6-(Bromoacetyl)Amino-2,3-Dimorpholino-Quinoxaline and Application to a new Fluorescence Derivatization Reagent of Fatty Acids for the High-Performance Liquid Chromatographic Analysis”, H… [cited by applicant]
Katz, L., et al., “Hydrazine Derivatives. II. Ortho-Mercapto-Pyridinecarbohydrazides”, J. Org. Chem., 1954, 19(5):711-717. [cited by applicant]
Klein, T. W., et al., “The Cannabinoid system and immune modulation”, J. Leukocyte Biology, 2003, 74(4):486-496. [cited by applicant]
Kolehmainen, E. et al., “α-Phenylsulfonyl-N-arylacetamides (α-phenylsulfonylacetanilides): 1H,13C and 15N NMR spectral characterization”, Magnetic Resonance in Chemistry, 2000, 38(5):384-385. [cited by applicant]
Krutosikova, A. et al., “Furan derivatives. LV. Preparation of 5-aryl-2-furfuryl phenyl and 5- ary1-2-furfury1 4-tolyl sulfones”, Chernick Zvesti (Chemical Papers), 1974, 28(3):414-417. [cited by applicant]
Kulkarni, S.S. et al., “Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists”, Bioorg Med Chem Lett., 2006, 16(13):3371-3375. [cited by applicant]
Lambeng, N. et al., “Discovery of a Novel Piperidinyl-Sulfonyl Benzoic Ester, Active as CB1 Agonist” Poster. 231st ACS National Meeting, Atlanta, GA. Mar. 26-30, 2006. [cited by applicant]
Leberre, A. et al., “No. 150—Alpha-sulfocarboxylic acids and derivatives. V.—Acyclic sulfamoyl carboxyesters and carboxamides. 1,2-Thiazetidine 3-one 1,1-dioxides” Bulletin De La Societe Chimique De France, 1975, pp. 80… [cited by applicant]
Lesser, R. et al. “Uber das Homo—oxythionaphthene (4-Ketoisothiochromane”. Berichte, 1923, pp. 1642-1648. [cited by applicant]
Li, S. et al., “The Synthesis and Preliminary Activity Assay In Vitro of Peptide-like Derivatives as APN Inhibitors.” Archives of Pharmacal Research, 2008, 31(10):1231-1239. [cited by applicant]
Lutz, R. E. et al., “Antimalarials. Some piperazine derivatives”, Journal of Organic Chemistry, 1947, 12(6):771-775. [cited by applicant]
Mahmoud, A. M. et al., “Synthesis and Biological Activity of Some new 2-(N-Substituted Carboxamidomethyl Thio)-Naphth[1,2-d]Oxazoles—Part V”, J. Indian Chem. Soc., vol. LIX, May 1982, DD. 675-677. [cited by applicant]
Malan Jr., T. P., et al., “CB2 cannabinoid receptor-mediated peripheral antinociception”, Pain, 2001, 93(3):239-245. [cited by applicant]
Markley, L. D., et al., “Antipicornavirus activity of substituted phenoxybenzenes and phenoxypyridines”, J. Med. Chem., 1986, 29( )3:427-433. [cited by applicant]
Marx, I. E. et al., “Discovery of α-amidosulfones as potent and selective agonists of CB2: Synthesis, SAR, and pharmacokinetic properties”, Bioorganic and Medicinal Chemistry Letters, 2009, 19(1):31-35. [cited by applicant]
Messinger, P., “Sulfones via Mannich bases” Archiv der Pharmazie, 1973, 306(8):603-610. [cited by applicant]
Miroshnikova, O.V. et al., “Structure-activity relationships in the series of eremomycin carboxamides”, Journal of Antibiotics, 2000, 53(3):286-293. [cited by applicant]
Miyano, S, et al., “Kinetic Resolution of Racemic b-Hydroxy Amines by Enantioselective N-Oxide formation”, Journal of Organic Chemistry, 1985, 50(22):4350-4360. [cited by applicant]
Mohler, et al., “Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates”, Expert Opinion of Therapeutic Patents; Nov. 15, 2005 (11):1565-1585. [cited by applicant]
Nackley, A. G., et al., “Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation”, Neuroscience, 2003, 119(3):747-757. [cited by applicant]
Pollard, C. B. et al., “Some amides of piperazines”, Journal of American Chemical Society, 1953, 75(2):491. [cited by applicant]
Revesz, L. et al., “Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis”, Bioorganic and Medicinal Chemistry Letters, 2005, 15(23):5160-5164. [cited by applicant]
Riether, D. “Discovery of a Novel Class of CB2 Receptor Agonists” Abstract of Presentation at the first International Conference devoted to studies of the CB2 cannabinoid receptor. Banff, Alberta, Canada, May 31-Jun. 3,… [cited by applicant]
Sakuraba, S, et al., “Efficient asymmetric hydrogenation of a-amino ketone derivatives. A highly enantioselective synthesis of phenylephrine, levamisole, carnitine and propranolol”. Chemical and Pharmaceutical Bulletin,… [cited by applicant]
Schafer, H. et al. “On the Synthesis of 4-aminoquinolines and -quinolinones-(2) from Anthranilonitrile”, Journal for Practical Chemistry, 1979, 321(4):695-698. [cited by applicant]
Seidel M. C. et al., “Reaction of Substituted 2-Carbethoxyacetyl-aminopyridines and Similar Compounds with Triethyl Orthoformate and Zinc Chloride,” J. Org. Chem., 1970, 35(5):1662-1664. [cited by applicant]
Sheehan, J.C. et al., “The Synthesis and Reactions of Some Substituted Beta-Lactams,” J. Am. Chem. Soc., 1951, 73:1761-1765. [cited by applicant]
Silverman, Richard B., The Organic Chemistry of Drug Design and Drug Action, 2nd Edition, 2004, Elsevier, pp. 29-34. [cited by applicant]
Sisko, J. et al., “An investigation of imidazole and oxazole syntheses using aryl-substituted TosMIC reagents”, The Journal of Organic Chemistry, Mar. 10, 2000, 65(5):1516-1624, ISSN: 022-3263, p. 1523, table 5,; compou… [cited by applicant]
Smith, S. R., et al., “The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models”, Eur. J. Pharmacology, 2001, 432:p. 107. [cited by applicant]
Stalberg et al. “Capillary Electrophoretic Separation of Basic Drugs Using Surface-Modified C8 Capillaries and Derivatized Cyclodextrins as Structural/Chiral Selectors.” Chromatographia, 1995, 40(11/12):697-704. [cited by applicant]
STN results for Dorme et al., “Bulletin de la Societe Chimique de France”; 1959, 9:2582-2588. [cited by applicant]
Strating, J., et al. “Nucleophilic Additions to Bis-Tertiobutyl Sulfonyl Acetylene (Properties of the sulfonyl group XLIV)”, Recueil, 1954, pp. 709-716. [cited by applicant]
Swanson, D. M. et al., “Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-y1)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor anta… [cited by applicant]
Tegley, et al., “Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation,” Bioorganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science, GB, 2008,… [cited by applicant]
Todorova, T. R., et al.“Ring-enlargement and ring-opening reactions of 1,2-thiazetidin-3-one 1,1,-dioxides with ammonia and primary amines as nucleophiles”. Helvetica Chimica Acta, 1999, 82(3):354-371. [cited by applicant]
Trang, T. et al., “Pain and Poppies: The Good, the Bad, and the Ugly of Opioid Analgesics”, J. Neurosci., 2015, 35(41):13879-13888. [cited by applicant]
Troeger, J. and Uhde, R., “Lieber sulfonirte buttersauren”, J. Prakt. Chem., 1899, 59:320-349. [cited by applicant]
Tweit, R. C., et al., “Synthesis of Antimicrobial Nitroimidazolyl 2-Sulfides, -Sulfoxides, and -Sulfones”, J. Med. Chem., 1973, 16:1161-1169. [cited by applicant]
Ueda, Y., et al., “Involvement of cannabinoid CB2 receptor-mediated response and efficacy of cannabinoid CB2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice”, Eur. J. Pharmacol., 2005, 520(1-3):164-… [cited by applicant]
Van Sickle, et al., “Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors”, Science, 2005, 310(5746):329-332. [cited by applicant]
Venkov, A.P. et al., “A new synthesis of 1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinolines”, Synthesis, 1990, 1990(3):253-255. [cited by applicant]
Vogtle, M. M. et al., “An efficient protocol for the solid-phase synthesis of malondiamides”, Molecules, 2005, 10(12):1438-1445. [cited by applicant]
Walker, G.N. et al., “Synthesis of Varied Heterocyclic and Substituted Aryl Alkyl Secondary Amines, Related Schiff Bases, and Amides”, Journal of Medicinal Chemistry, 1966, 9(4):624-630. [cited by applicant]
Wang, Y. et al., “Rapid and efficient synthesis of 1,2,4-oxadiazoles utilizing polymer-supported reagents under microwave heating”, Organic Letters, Mar. 3, 2005, 7(5):925-928, ISSN: 1523-7060, p. 927, compounds; 14,15. [cited by applicant]
Watson, R. J., et al., “An enantioselective synthesis of sulphonamide hydroxamic acids as matrix metalloproteinase inhibitors”, Tetrahedron Letters, 2002, 43(4):683-685. [cited by applicant]
Wei, Ling et al., “Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amides ”, Bioorganic & Medicinal Chemistry Letters, 2002, 12 (10):1429-1433. [cited by applicant]
Wermuth, C. G., “The Practice of Medicinal Chemistry”, 2008, Third Edition, Ch. 17, pp. 363-379. [cited by applicant]
White, J.D. et al., “Conversion of Carbamates to Amidosulfones and Amides. Synthesis of the [14C]-Labeled Antiobesity Agent Ro23-7637”, Organic Letters, Apr. 17, 2002, 4(10):1803-1806. [cited by applicant]
Yang, G. et al., “Synthesis and bioactivity of novel triazolo [1,5-a]pyrimidine derivatives[3]”, Heteroatom Chemistry, 2001, 12(6):491-496. [cited by applicant]
Yokoyama, M. et al., “A regioselective synthesis of 3,5-disubslituted isoxazoles”. J. Chem. Soc. Perkin Trans. I, 1986, pp. 67-72. [cited by applicant]
Yordanova, K. et al. “New method for the synthesis of 2,4-disubslituted morpho-lines”, Chem. Ber., 1982, 115:2635-2642. [cited by applicant]
Zhang, B. and Breslow, R., “Ester Hydrolysis by a Catalytic Cyclodextrin Dimer Enzyme Mimic with a Metallobipy Metallobipyridyl ridvl Linkina Group”, J. Am. Chem. Soc., 1997, 119(7):1676-1681. [cited by applicant]
Zimmer, A. et al., “Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice”, Proc. Natl. Acad. Sci. USA, 1999, 96(10):5780-5785. [cited by applicant]
Zindell, R. et al., “Discovery of a novel class of CB2 agonists”. General Poster Session. The 235th ACS National Meeting, New Orleans, LA, USA. Apr. 6-10, 2008. [cited by applicant]
Office Action dated Mar. 22, 2010, from the European Patent Office for Application # 078132032. [cited by applicant]
Office Action mailed Jan. 13, 2012, for U.S. Appl. No. 12/882,328, filed Sep. 15, 2010. [cited by applicant]
Office Action mailed Jan. 27, 2012, for U.S. Appl. No. 12/741,260, filed Jun. 17, 2010. [cited by applicant]